

Pfizer's commitment to genitourinary cancer medicine.

Powered by experience. Led by science. Driven by patient care.

With proven leadership in genitourinary (GU) cancer care, Pfizer is committed to transforming the treatment landscape for people with these pervasive and hard-to-treat cancers.

Our commitment extends to include programs and support for GU cancers.



Our portfolio includes six approved medicines to treat people living with prostate, kidney and bladder cancers in the United States.



We are grounded in the science of GU cancers through clinical investments, collaborations and a robust pipeline and portfolio.



We work closely with the entire cancer community to understand the needs of patients, families, and caregivers.

